Adaptin Bio (APTN) EPS (Basic) (2023 - 2026)

Adaptin Bio (APTN) has 4 years of EPS (Basic) data on file, last reported at -$0.13 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Basic) fell 27.26% year-over-year to -$0.13; the trailing twelve-month figure through Mar 2026 stood at -$0.66 (down 13.69% YoY), and the FY2025 full-year result was -$0.52, down 6.9% from the prior year.
• EPS (Basic) grew to -$0.13 in Q1 2026, from -$0.18 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q3 2023 to a low of -$0.22 in Q3 2024.
• A 4-year average of -$0.13 and a median of -$0.16 in 2024 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) slumped 2479.42% in 2024 and rose 10.54% in 2025, its largest moves.
• Tracing APTN's EPS (Basic) over 4 years: stood at -$0.01 in 2023, then plunged by 1098.94% to -$0.17 in 2024, then decreased by 4.95% to -$0.18 in 2025, then gained by 24.79% to -$0.13 in 2026.
• Business Quant data shows APTN's EPS (Basic) at -$0.13 in Q1 2026, -$0.18 in Q4 2025, and -$0.2 in Q3 2025.